Remise en cause de la réalité d’une augmentation de la mortalité cardiovasculaire sous traitement par privation androgénique pour cancer de la prostate ?

Questioning the reality of an increase in cardiovascular mortality with androgen deprivation therapy for prostate cancer?

Basic and Clinical Andrologyvolume 21, pages227–229 (2011) | Download Citation

Références

1.
Buvat J, Maggi M, Gooren L, et al (2010) Endocrine aspects of male sexual dysfunctions. J Sex Med 7:1627–1656
2.
Corona G, Rastrelli G, Monami M, et al (2011) Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 165:1–18
- Article
- Google Scholar
3.
Punnen S, Cooperberg MR, Sadetsky N, Carroll PR (2001) Androgen deprivation therapy and cardiovascular risk. J Clin Oncol 29:3510–3516
- Article
- Google Scholar
4.
Efstathiou JA, Bae K, Shipley WU, et al (2008) Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 54:816–823
5.
Efstathiou JA, Bae K, Shipley WU, et al (2009) Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 27:92–99
6.
Von Eckardstein A, Wu FCW (2004) Testosterone and cardiovascular diseases. In Nieschlag E, Behre HM (eds) Testosterone Action, Deficiency, Substitution. Cambridge University Press, Cambridge, pp 297–332
- Google Scholar
7.
McGrath KC, McRobb LS, Heather AK (2008) Androgen therapy and atherosclerotic cardiovascular disease. Vasc Health Risk Manag 4:11–21

Correspondence to J. Buvat.